

# Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis

<b>Submission date</b> 02/04/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/05/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 27/04/2016	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Lieske Kuitert

**Contact details**  
Department of Respiratory Medicine  
London Chest Hospital  
Bonner Road  
London  
United Kingdom  
E2 9JX

## Additional identifiers

**Protocol serial number**  
vit K 2006

## Study information

**Scientific Title**

Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis

**Study objectives**

Vitamin K supplementation improves markers of bone turnover and bone density in adolescents and adults with cystic fibrosis (CF).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Wandsworth Research Ethics Committee, 11/08/2006 (protocol v4), 18/05/2007 (amendments protocol v5) and 03/08/2007 (amendments protocol v6).

**Study design**

Randomised double-blind placebo-controlled study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Bone health in cystic fibrosis

**Interventions**

1. 10 mg of menadiol phosphate (water soluble form of vitamin K) once daily (o.d.) orally for 12 months
2. Matching placebo for 12 months

Total duration of treatment and follow-up: 12 months for both arms.

**Intervention Type**

Supplement

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Vitamin K supplementation

**Primary outcome(s)**

The between-groups difference in the ratio of undercarboxylated osteocalcin to total osteocalcin, measured prior to supplementation starting and at the end of the 12 months supplementation.

**Key secondary outcome(s)**

The between-group differences in:

1. Total osteocalcin
2. Undercarboxylated osteocalcin

3. N Terminal X (marker of bone resorption)
4. Bone specific alkaline phosphatase
5. Serum vitamin D
6. Calcium
7. Dual energy x-ray absorptiometry (DEXA) scan z and t scores of lumbar spine and femoral neck (scores adjusted for age, height and sex)

Measured prior to supplementation starting and at the end of the 12 months supplementation.

**Completion date**

09/02/2009

## Eligibility

**Key inclusion criteria**

1. Patients with a diagnosis of CF (positive sweat test or genotype testing)
2. Patients aged greater than 16 years (post pubertal-stage IV Tanner), either sex
3. Patients are pancreatic insufficient (i.e. with a positive faecal elastase test, and requiring pancreatic enzyme supplementation)
4. No evidence of overt liver disease (not on ursodeoxycholic acid)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Patients already taking vitamin K supplementation
2. Patients with osteoporosis or osteopaenia and taking bisphosphonates
3. Patients with abnormally low vitamin D levels (less than 30 µg)
4. Patients on maintenance oral corticosteroids
5. Patients who are considered to have very sedentary lifestyle or follow a rigorous exercise training programme
6. Patients with overt liver disease
7. Patients who do not consent to participate
8. Patients with a life expectancy of less than 12 months
9. Patients who are non-compliant with maintenance therapies

**Date of first enrolment**

02/01/2007

**Date of final enrolment**

09/02/2009

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Department of Respiratory Medicine

London

United Kingdom

E2 9JX

# Sponsor information

## Organisation

Barts and the London NHS Trust (UK)

## ROR

<https://ror.org/00b31g692>

# Funder(s)

## Funder type

Government

## Funder Name

Barts and the London NHS Trust (UK) - Internally funded from Nursing, Midwifering and Allied Health Profession research grant

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration